checkAd
    Startseite > Aktien > Revive Therapeutics > Nachrichten
    Revive Therapeutics Aktie
    0,0200
     
    EUR
    0,00 %
    0,0000 EUR
    Letzter Kurs 18:47:09 Lang & Schwarz
    0,0100
     
    EUR
    465.116 STK
    Geldkurs 18:47:09
    0,0300
     
    EUR
    465.116 STK
    Briefkurs 18:47:09
    ISIN: CA7615161030 · WKN: A2AP4F · Kanada

    Neueste Nachrichten

    Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
    23.04.24 · globenewswire · Revive Therapeutics
    Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
    18.04.24 · globenewswire · Revive Therapeutics
    Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
    02.04.24 · globenewswire · Revive Therapeutics
    Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
    27.03.24 · globenewswire · Revive Therapeutics
    Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
    19.03.24 · globenewswire · Revive Therapeutics
    Revive Therapeutics Provides Corporate Update
    12.03.24 · globenewswire · Revive Therapeutics
    Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
    26.02.24 · globenewswire · Revive Therapeutics
    Revive Therapeutics Explores the Use of Bucillamine for Long COVID
    01.02.24 · globenewswire · Revive Therapeutics
    Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
    31.01.24 · globenewswire · Revive Therapeutics
    Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
    24.01.24 · globenewswire · Revive Therapeutics
    Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
    16.01.24 · globenewswire · Revive Therapeutics
    Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
    10.01.24 · globenewswire · Revive Therapeutics